Cochrane · systematic review · CD001555
Treatment for inclusion body myositis
Rose, MR, Jones, K, Leong, K, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
5
No studies
19
Included studies
NR
No studies 19 · 52.8%Ungraded 12 · 33.3%Very low 1 · 2.8%Low 0 · 0%Moderate 4 · 11.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intravenous immunoglobulin versus placebo for inclusion body myositis
Population: people with inclusion body myositis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in muscle strength at 6 months (%) Intravenous immunoglobulin vs placebo | no estimate extracted | 3 studies · 78 participants | Ungraded |
Change in muscle strength at 12 months (%) ‐ not measured Intravenous immunoglobulin vs placebo | no estimate extracted | NR | No studies |
Change in muscle mass at 6 months (%) ‐ not measured Intravenous immunoglobulin vs placebo | no estimate extracted | NR | No studies |
Change in handgrip strength at 6 months (%) ‐ not measured Intravenous immunoglobulin vs placebo | no estimate extracted | NR | No studies |
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured Intravenous immunoglobulin vs placebo | no estimate extracted | NR | No studies |
Significant adverse events Intravenous immunoglobulin vs placebo | no estimate extracted | 3 studies · 78 participants | Ungraded |
Interferon beta‐1a compared to placebo for inclusion body myositis
Population: people with inclusion body myositis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in muscle strength at 6 months (normalised MMT score ‐ see Characteristics of Studies table) Interferon beta‐1a vs placebo | no estimate extracted | 2 studies · 58 participants | Moderate |
Change in muscle strength at 12 months (%) ‐ not measured Interferon beta‐1a vs placebo | no estimate extracted | NR | No studies |
Change in muscle mass at 6 months (%) Interferon beta‐1a vs placebo | no estimate extracted | 2 studies · 58 participants | Moderate |
Change in handgrip strength at 6 months (%) Interferon beta‐1a vs placebo | no estimate extracted | 2 studies · 58 participants | Ungraded |
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured Interferon beta‐1a vs placebo | no estimate extracted | NR | No studies |
Significant adverse events Interferon beta‐1a vs placebo | no estimate extracted | 2 studies · 58 participants | Ungraded |
Methotrexate compared to placebo for inclusion body myositis
Population: people with inclusion body myositis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in muscle strength at 6 months (%) Methotrexate vs placebo | no estimate extracted | 1 study · 44 participants | Ungraded |
Change in muscle strength at 12 months (%) ‐ MMT Methotrexate vs placebo | no estimate extracted | 1 study · 44 participants | Moderate Downgraded: imprecision |
Change in muscle mass at 6 months (%) ‐ not measured Methotrexate vs placebo | no estimate extracted | NR | No studies |
Change in handgrip strength at 6 months (%) ‐ not measured Methotrexate vs placebo | no estimate extracted | NR | No studies |
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured Methotrexate vs placebo | no estimate extracted | NR | No studies |
Significant adverse events Methotrexate vs placebo | RR 8.76 [1.19, 64.28] | 1 study · 44 participants | Moderate Downgraded: imprecision |
Methotrexate and anti‐T lymphocyte immunoglobulin compared to methotrexate for inclusion body myositis
Population: people with inclusion body myositis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in muscle strength at 6 months (%) Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate | no estimate extracted | 1 study · 11 participants | Ungraded |
Change in muscle strength at 12 months (%) ‐ QMT Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate | no estimate extracted | 1 study · 11 participants | Very low Downgraded: risk of bias |
Change in muscle mass at 12 months (%) ‐ not measured Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate | no estimate extracted | NR | No studies |
Change in handgrip strength at 6 months (%) Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate | no estimate extracted | 1 study · 11 participants | Ungraded |
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate | no estimate extracted | NR | No studies |
Significant adverse events Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate | no estimate extracted | 1 study · 11 participants | Ungraded |
Methotrexate and azathioprine compared to methotrexate (plus leucovorin) for inclusion body myositis
Population: people with inclusion body myositis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in muscle strength at 6 months (%) Methotrexate and azathioprine vs methotrexate (plus leucovorin) | no estimate extracted | 1 study · 11 participants | Ungraded |
Change in muscle strength at 12 months (%) (using MMT or QMT) at 12 months ‐ not measured Methotrexate and azathioprine vs methotrexate (plus leucovorin) | no estimate extracted | NR | No studies |
Change in muscle mass at 6 months (%) ‐ not measured Methotrexate and azathioprine vs methotrexate (plus leucovorin) | no estimate extracted | NR | No studies |
Change in handgrip strength at 6 months (%) ‐ not measured Methotrexate and azathioprine vs methotrexate (plus leucovorin) | no estimate extracted | NR | No studies |
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured Methotrexate and azathioprine vs methotrexate (plus leucovorin) | no estimate extracted | NR | No studies |
Significant adverse events Methotrexate and azathioprine vs methotrexate (plus leucovorin) | no estimate extracted | 1 study · 11 participants | Ungraded |
Oxandrolone compared to placebo for inclusion body myositis
Population: people with inclusion body myositis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in muscle strength at 6 months (%) Oxandrolone vs placebo | no estimate extracted | 1 study · 16 participants | Ungraded |
Change in muscle strength at 12 months (%) ‐ not measured Oxandrolone vs placebo | no estimate extracted | NR | No studies |
Change in muscle mass at 6 months (%) Oxandrolone vs placebo | no estimate extracted | 1 study · 16 participants | Ungraded |
Change in handgrip strength at 6 months (%) ‐ not measured Oxandrolone vs placebo | no estimate extracted | NR | No studies |
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured Oxandrolone vs placebo | no estimate extracted | NR | No studies |
Significant adverse events Oxandrolone vs placebo | no estimate extracted | NR | No studies |